The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
This project involves a unique interdisciplinary approach combining bioinformatics, biostatistics and mathematical biology to better understand the dynamics of infection and immunity. Using data from in vitro studies, animal models, and human infections, I aim to understand immune control and pathogen growth and evolution in HIV and malaria infection.
Translating Research Into HIV-related Health Outcomes In The Developing World
Funder
National Health and Medical Research Council
Funding Amount
$714,745.00
Summary
Professor Crowe's research addresses important health issues for HIV infected people living in resource limited countries. Her team validates low cost point of care tests to monitor HIV infection, including a test she co-developed to determine when to start anti-HIV treatment, and investigates how these low cost tests can improve clinical care of people with HIV and TB. In addition she will determine how changes in the immune system increase the risk of heart attacks in young HIV patients.
This fellowship is to support Professor Stephen Kent in generating new advances in vaccines to prevent HIV (the cause of AIDS) and Influenza (“The Flu”). HIV causes over 1.5 million deaths per year and no vaccine is currently available. Influenza causes around half a million deaths per year. Although the current Influenza vaccine is partially effective, improvements are needed for it to be able to protect against the many different strains of Influenza that can cause infection.
Research Fellowship In Preventing HIV And HIV-related Cancer
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
This fellowship concerns HIV prevention and HIV-related cancer. In HIV prevention, Grulich will evaluate the success of elements of the new biomedical prevention approach to HIV, and highlight areas in which policy action can be taken to substantially reduce HIV transmission. In HIV related cancer, Grulich will determine whether HIV-associated cancers continue to occur at increased rates in the new era of prolonged survival of people with HIV, and investigate preventive approaches.
Advancing Nanomedicine Through Particle Technology
Funder
National Health and Medical Research Council
Funding Amount
$876,005.00
Summary
This proposal will support the development of advanced particle systems to improve the delivery of medicines in neurological diseases, HIV, diabetes and cancer. It will provide important insights for particle-based therapeutic delivery that are expected to underpin progress on nanotechnology in the areas of biology and medicine. These developments in nanotechnology-enabled medicines towards commercialisation will ultimately improve the health and quality of life of Australians.
Targeting Host Pathogen Interactions And Signalling Networks To Promote Death Of Infected Cells And Facilitate Pathogen Clearance
Funder
National Health and Medical Research Council
Summary
Preclinical models of infectious diseases including hepatitis B, HIV, tuberculosis and human herpes virus infections will be used to understand how pathogens interact with host cells. With this understanding we aim to identify which host cell signalling pathways play a critical role in limiting or faciliating pathogen persistence. After identifying the important cellular pathways we aim to target these host cell signalling components with clinical stage drugs to promote pathogen clearance.
Towards HIV And Hepatitis C Elimination: Real-world Trials And Innovations In Disease Surveillance
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Over the next five years I will undertake a program of research centred on developing and implementing strategies to help eliminate hepatitis C and HIV as major public health problems. In particular, I will use innovative monitoring systems and field trials to explore ways to diagnose and treat HIV and hepatitis C in vulnerable populations in a more timely way and study the influence this has on reducing the onward transmission of these infections to others.
Treatment And Prevention Of HIV And Sexually Transmitted Infections
Funder
National Health and Medical Research Council
Funding Amount
$772,490.00
Summary
My research will use statistical and mathematical models to answer questions in the prevention and treatment of infectious diseases. I will assess long-term outcomes in HIV positive patients, including developing risk prediction models to improve patients monitoring. I will look at strategies to improve antiretroviral treatment in developing countries in Asia. And I will identify optimal preventions strategies to reduce rates of sexually transmitted infections.
Evaluations For Efficient And Effective Public Health Responses To HIV Epidemics
Funder
National Health and Medical Research Council
Funding Amount
$699,190.00
Summary
I will lead studies on evaluating population impact and calculating cost-effectiveness of public health prevention programs for HIV/AIDS epidemics in Asia and Eastern Europe. Return on Investment analyses will inform Ministries of Finance about overall budget allocations. Effectiveness and efficiency evaluations and determining optimal allocations of funding mixes will directly inform Ministries of Health in planning program implementation in 15-20 countries in the region.
HIV/AIDS remains a major global threat with ?37 million individuals living with HIV in 2014. Antiretroviral drugs have transformed HIV from a death sentence into a chronic disease. Public health organisations recommend dramatic scale up of drugs for HIV treatment and prevention. However, a major threat is that drug options will be exhausted in the long-term due to drug resistance and toxicity. The major aim of this study is to advance the development of an entirely new drug class for HIV.